Discontinued — last reported Q2 '22
Business Segments · Revenue
Life Sciences — Revenue
Becton, Dickinson and Company Life Sciences — Revenue increased by 515.4% to $4.71B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.2%, from $4.48B to $4.71B. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ3 2015
Last reportedQ2 2022
Rolls up toTotal Revenue
How to read this metric
An increase indicates strong market adoption of diagnostic and research technologies, while a decrease may signal competitive pressure or reduced laboratory spending.
Detailed definition
This represents the total gross sales generated by the Life Sciences business segment, which focuses on diagnostic instr...
Peer comparison
Comparable to revenue reporting for life science tools and diagnostics segments in peer medical technology firms.
Metric ID:
bdx_segment_life_sciences_revenuesHistorical Data
39 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.61B | $1.43B | $4.30B | $1.53B | $4.72B | $1.48B | $4.75B | $1.49B | $4.64B | $1.31B | $4.76B | $1.29B | $4.59B | $1.30B | $4.82B | $1.28B | $4.88B | $1.23B | $5.09B | $1.33B | $4.71B | $1.29B | $5.05B | $1.30B | $4.99B | $1.26B | $5.44B | $1.34B | $5.17B | $1.30B | $4.48B | $1.25B | $5.51B | $1.25B | $6.68B | $1.37B | $5.25B | $766.00M | $4.71B |
| QoQ Change | — | -68.9% | +200.2% | -64.4% | +208.0% | -68.6% | +220.3% | -68.7% | +212.5% | -71.8% | +263.7% | -73.0% | +256.3% | -71.6% | +270.3% | -73.6% | +282.6% | -74.9% | +314.9% | -73.9% | +253.8% | -72.6% | +291.7% | -74.2% | +282.7% | -74.7% | +331.5% | -75.4% | +286.0% | -74.9% | +245.4% | -72.2% | +341.8% | -77.2% | +432.9% | -79.5% | +283.6% | -85.4% | +515.4% |
| YoY Change | — | — | — | — | — | — | — | — | +0.7% | -71.6% | +10.7% | -70.1% | -2.8% | -72.4% | +1.5% | -73.2% | +5.1% | -73.6% | +6.8% | -72.1% | +2.6% | -71.9% | +4.6% | -73.0% | +2.3% | -74.2% | +6.9% | -73.7% | +9.8% | -72.4% | -11.2% | -75.3% | +10.4% | -74.9% | +22.9% | -74.8% | +1.6% | -85.2% | +5.2% |
Range$766.00M – $6.68B
CAGR+0.2%
Avg YoY Growth-33.3%
Median YoY Growth-11.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's life sciences — revenue?
- Becton, Dickinson and Company (BDX) reported life sciences — revenue of $4.71B in Q1 2026.
- How has Becton, Dickinson and Company's life sciences — revenue changed year-over-year?
- Becton, Dickinson and Company's life sciences — revenue increased by 5.2% year-over-year, from $4.48B to $4.71B.
- What does life sciences — revenue mean?
- Total revenue generated specifically by the Life Sciences business unit.